Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

Lean Rx vs MyDrHank

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #297
Lean Rx

Lean Rx is a Sacramento-based telehealth technology platform offering compounded GLP-1 weight loss medications.

Marked down on: Compounded-only; no FDA-approved branded options

vs
Dispatch #104Desk pick
MyDrHank

Every price MyDrHank advertises is the cheapest rung of a four-term ladder — its own code renders the annual-prepay rate as “From $X/mo”, so the month-to-month cost of $349 tirzepatide and $259 semaglutide appears nowhere in the marketing.

Marked down on: Every advertised price is an annual-prepay minimum. The site's own code takes the cheapest rung of a four-term ladder and prints it as “From $X/mo”, so the $240/mo tirzepatide and $171/mo semaglutide it markets are what $2,883 and $2,057 paid up front work out to per month — the month-to-month rates, $349 and $249, are displayed nowhere, and the FAQ still calls the prepay figure a plan with “no contract”

MyDrHank takes this head-to-head with the higher Desk Score, 73/100 (C) against 61/100 (C) for Lean Rx. Lean Rx still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Lean Rx

61/100

C

Overall

MyDrHank

73/100

C

Price transparency

78
52

State access

24
72

Molecule range

77
88

Onboarding speed

56
88

Support responsiveness

66
74

Licensing & trust

68
76

The spec sheet

FieldLean RxMyDrHank
Semaglutide$266/mo (starting dose, compounded)$259/mo month-to-month (compounded injectable; oral $249/mo; the advertised $171/mo is a $2,057 annual prepay)
Tirzepatide$399/mo (starting dose, compounded)$349/mo month-to-month (compounded; the advertised $240/mo is a $2,883 annual prepay)
CoverageCoverage not published44 states (excludes Kansas, Louisiana, Mississippi, New Mexico, North Dakota, West Virginia)
Brand-nameCompounded onlyCompounded only
Oral optionYesYes
Best forPatients wanting compounded GLP-1 in injectable, sublingual, or tablet form.Readers who intend to pay for a full year up front and will do the arithmetic first — at the month-to-month rate this is one of the dearer compounded desks the Desk tracks.
Desk Score61/100C73/100C

The verdict

Desk pick — MyDrHank

MyDrHank takes this head-to-head with the higher Desk Score, 73/100 (C) against 61/100 (C) for Lean Rx. Lean Rx still holds its ground where its strengths line up with yours.

Choose Lean Rx if…

Patients wanting compounded GLP-1 in injectable, sublingual, or tablet form.

$266/mo (starting dose, compounded) sema · $399/mo (starting dose, compounded) tirz · Coverage not published

Choose MyDrHank if…

Readers who intend to pay for a full year up front and will do the arithmetic first — at the month-to-month rate this is one of the dearer compounded desks the Desk tracks.

$259/mo month-to-month (compounded injectable; oral $249/mo; the advertised $171/mo is a $2,057 annual prepay) sema · $349/mo month-to-month (compounded; the advertised $240/mo is a $2,883 annual prepay) tirz · 44 states (excludes Kansas, Louisiana, Mississippi, New Mexico, North Dakota, West Virginia)

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Lean Rx · MyDrHank.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.